PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; tovorafenib and dordaviprone for glioma, mirvetuximab soravtansine and pembrolizumab for ovarian cancer, tislelizumab for nasopharyngeal cancer, trastuzumab deruxtecan, palbociclib and datopotamab deruxtecan for breast cancer, epcoritamab for lymphoma, teclistamab for multiple myeloma

Unresolved referenced work

Kept as external metadata until matched

10.1038/s41591-023-02668-y

10.1038/s41591-023-02668-y · 2024

10.1056/nejmoa2309169

10.1056/nejmoa2309169 · 2023

10.1200/jco.23.01134

10.1200/jco.23.01134 · 2024

10.1016/j.ccell.2023.04.014

10.1016/j.ccell.2023.04.014 · 2023

10.1056/nejmoa2508668

10.1056/nejmoa2508668 · 2026

10.1016/s0140-6736(26)00602-1

10.1016/s0140-6736(26)00602-1 · 2026

10.1016/s0140-6736(25)02360-8

10.1016/s0140-6736(25)02360-8 · 2026

10.1056/nejmoa2511218

10.1056/nejmoa2511218 · 2026

10.1056/nejmoa2514663

10.1056/nejmoa2514663 · 2026

10.1016/j.annonc.2026.03.008

10.1016/j.annonc.2026.03.008 · 2026

Unresolved referenced work